Registered Rwanda · Rwanda FDA

LEVOBUPIVACAINE

Levobupivacaine hydrochloride

Rwanda FDA-HMP-MA-2246 Solution for injection 56.33 mg/ ampoule nervous system INN generic

What it does

Levobupivacaine is a local anesthetic used to numb a specific area of the body during medical procedures.

Commonly used for: pain relief during surgery, regional anesthesia, local anesthesia

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-2246
Registration date
04/02/2025
Expiry date
03/02/2030
Status
Registered
Active ingredient
Levobupivacaine hydrochloride
Strength
56.33 mg/ ampoule
Pack size
5x10 ml ampoules
Therapeutic class
-
ATC class (WHO)
N01BB - Amides
Drug group
NERVOUS SYSTEM
RxNorm RxCUI
259453
Manufacturer / MAH
Altan Pharmaceuticals
Applicant / LTR
Altan Pharma Ltd/ Ireland
Country of origin
SPAIN
Manufacturer location
C. Cólquide, 6, 28231 Las Rozas de Madrid, Madrid, Spain

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:03 · updated 2026-09-21 02:30:19

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Levobupivacaine is a local anesthetic used to numb a specific area of the body during medical procedures.

What it treats

  • pain relief during surgery
  • regional anesthesia
  • local anesthesia

How it works

It blocks nerve signals in the area where it is applied, preventing sensation of pain.

Who it's for

Adults and children undergoing surgical procedures or requiring pain management.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Levobupivacaine

BNF-referenced

Levobupivacaine is a local anesthetic agent, a pure S-enantiomer of bupivacaine, commonly used to provide regional anesthesia. It is indicated for various surgical procedures, including obstetrical, oral, and diagnostic interventions. The drug is recognized for its effectiveness in pain management during and after surgical procedures, balancing efficacy with a favorable safety profile. It acts primarily by blocking nerve conduction, making it essential in both acute and postoperative pain management.

Indications

  • Local anaesthesia
  • Surgical anaesthesia
  • Acute postoperative pain
  • Obstetrical procedures

Dosage

Children: Dosing in children should be determined according to the child's physical status and the nature of the procedure, as specified in the BNF for Children.

Adults: For surgical anaesthesia via lumbar epidural, the typical adult dose is 75-150 mg, administered over 15-20 minutes using a 5 mg/mL (0.5%) solution. For intrathecal injection, 15 mg is recommended. For local infiltration, doses may range from 2.5 to 150 mg, administered using a 2.5 mg/mL (0.25%) solution. The maximum daily dose should not exceed 400 mg.

Mechanism of action

Levobupivacaine blocks the generation and conduction of nerve impulses by binding to the intracellular portion of sodium channels in nerve cells. This action prevents sodium influx, which is essential for depolarization, thereby increasing the threshold for electrical excitation and slowing nerve impulse propagation.

Pharmacodynamics

Levobupivacaine induces local or regional anesthesia by effectively blocking nerve conduction. Its anesthetic effects are influenced by the diameter and myelination of nerve fibers, with a greater effect on larger, myelinated fibers. The drug is utilized in various clinical settings including surgical procedures, providing pain relief and facilitating interventions by maintaining patient comfort.

Pharmacokinetics

Levobupivacaine is absorbed following local administration, with its pharmacokinetic profile influenced by the route of administration and the site of injection. The drug undergoes hepatic metabolism, primarily by cytochrome P450 enzymes, and is excreted in urine. Its half-life and systemic exposure may vary based on patient factors, including hepatic and renal function.

Contra-indications

  • Hypersensitivity to levobupivacaine or other local anesthetics
  • Infection or inflammation at the injection site
  • Severe cardiovascular disease
  • Complete heart block
  • Severe hepatic impairment

Adverse effects

  • Neurological effects (e.g., dizziness, headache, back pain)
  • Cardiovascular effects (e.g., hypotension, arrhythmias)
  • Nausea
  • Apnoea
  • Angioedema
  • Bradycardia
  • Neonatal respiratory depression (after epidural block)

Interactions

  • Other local anesthetics
  • Drugs that affect cardiac conduction

Precautions

  • Use with caution in elderly patients or those with debilitation
  • Careful monitoring in patients with impaired cardiac conduction or respiratory function
  • Avoid excessive dosage in obese patients, dosing should be based on ideal body weight
  • Should only be administered by trained personnel with adequate resuscitation equipment available

Pregnancy

Use only if potential benefit outweighs risk, particularly in the first trimester. Caution advised due to potential toxicity in animal studies.

Breast-feeding

Amount too small to be harmful.

Storage

Protect from light.

Formulations

  • Solution for injection (various concentrations including 0.5% and 0.75%)
BNF 85 (British National Formulary) p.1512 BNF for Children 2019-2020 p.874 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Levobupivacaine

PubChem CID 92253

Molecular formula: C18H28N2O

Mechanism of action

Local anesthetics such as Levobupivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. Specifically, the drug binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, which prevents depolarization.

Pharmacodynamics

Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.